| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Oramed Pharmaceuticals Inc.$4.04
-0.14 (-3.35%)
B 63Pipeline Score Undervalued Pharma · Clinical
Market Cap
163.30 M
EPS
2.64
P/E Ratio
1.54 $
Value Trade
1.34 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
1.59 M
Operating CF
-2.92 M
Total Assets
268.85 M
Total Liabilities
268.85 M
Equity
238.28 M
D/E Ratio
12,345
-13.45 %
Week
3.37 %
1 Month
26.67 %
3 Month
65.56 %
6 Month
-63.73 %
5 Year
2,643.14 %
All Time
Cash Data
Cash Position
18.17 M
Monthly Burn
972.00 K
Runway
17.2 mo
Burn Trend
SEC Filing
May 19, 2026
Overview
Volume
226.91 K
52 Week Range
1.98 - 5.01
% held by Insiders
22.09 %
% held by Institutions
26.97 %
Enterprise Value
98.22 M
Total Shares
40.94 M
Short %
1.79 %
Float Shares
31.97 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Oramed Pharmaceuticals Inc.
556Total events
0Upcoming
108Tier-1 (high impact)
2008 – 2026Coverage
Event history 556
Jan 7, 2026
▲Milestone PaymentCorporate
Received $18 million payment from Scilex Holdings, closing out Option Agreement obligations
Oct 23, 2025
◆Trial Initiationoral insulinTrial
Initiating 60-patient US-based trial for oral insulin
diabetessource ↗
Oct 23, 2025
Sep 30, 2025
▲Equity OfferingCorporate
Additional open market purchases of Alpha Tau shares through Sep 30, 2025
Sep 30, 2025
Jul 1, 2025
Apr 28, 2025
▲Partnership / LicenseCorporate
Oramed closes $36.9M strategic investment in Alpha Tau and enters three-year service agreement
Apr 24, 2025
▲Equity OfferingCorporate
Investment in Alpha Tau Medical: $36.9M initial purchase on April 24, 2025
Mar 4, 2025
●NDA Submissionoral insulinRegulatory Filing
HTIT submitted Marketing Authorization Application to China's regulators for oral insulin capsule
diabetessource ↗
Mar 4, 2025
Drug Pipeline Intelligence
B63
Pipeline Score $2.4B
Pipeline ValueUndervalued
Valuation Signal5
Drugs Scored15.0x
rNPV / MCap Top 90%
Micro Cap (rank 92 of 911)
Percentile RankOramed Pharmaceuticals Inc. holds a solid B-grade pipeline (63/100), with $29.9B risk-adjusted pipeline value, led by ORMD-0801 in Type 2 Diabetes Mellitus (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORMD-0801 Small molecule | Type 2 Diabetes Mellitus | Phase 3 | NCT02954601 | 53% | $13.6B | COMPLETED | 331 | - | - | Mar 1, 2017 | LOW_RISK | Jul 11, 2018 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
oral insulin | type 2 diabetes | Phase 3 | 2023-05-15 | over 1% placebo adjusted, statistically significant, reduction in HbA1c Read More | Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China Read More | |
oral insulin | type 2 diabetes | Phase 3 | 2023-05-15 | over 1% placebo adjusted, statistically significant, reduction in HbA1c Read More | Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China Read More | |
oral insulin | type 2 diabetes | Phase 3 | 2023-05-15 | over 1% placebo adjusted, statistically significant, reduction in HbA1c Read More | Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ORMP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ORMP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ORMPOramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
Oramed Pharmaceuticals Inc. has announced its upcoming inclusion in the Russell 2000 and Russell 3000 indexes, effective June 29, 2026. This membership is based on market capitalization rankings and will enhance the company's visibility among investors. The Russell indexes are significant benchmarks for investment strategies, with trillions of dollars in assets tied to them.
Read more →ORMPOramed and Lifeward Announce Strategic Transaction
Oramed Pharmaceuticals has entered into a strategic transaction with Lifeward, transferring its Protein Oral Drug (POD™) delivery technology while acquiring a 49.9% ownership stake in Lifeward. The deal includes a $10 million investment in senior secured convertible notes. This partnership aims to enhance Oramed's exposure to oral drug delivery innovation and Lifeward's growth in medical robotics.
Read more →ORMP▲ +6.5%on this news
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
Oramed Pharmaceuticals has received an $18 million payment from Scilex Holdings, fulfilling its obligations under an Option Agreement. This payment increases Oramed's total returns from its Scilex investment to $118 million. Additionally, the Board has approved a cash dividend of $0.25 per share, set to be distributed on January 26, 2026, rewarding shareholders with an aggregate of approximately $10.5 million.
Read more →ORMPOramed Reports Fiscal Third Quarter 2025 Financial Results
Oramed Pharmaceuticals reported strong financial results for the nine months ending September 30, 2025, with total assets increasing by 42% to $220.5 million. The company's net income reached $65 million, largely due to cash returns from Scilex Holding Company and gains from investments in Alpha Tau Medical Ltd. CEO Nadav Kidron highlighted the effectiveness of their investment strategy in enhancing financial flexibility for future opportunities.
Read more →ORMPORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
Oramed Pharmaceuticals Inc. has announced a dividend distribution of common stock purchase rights to enhance shareholder protection against hostile takeovers. Each shareholder will receive one right per share, allowing them to purchase additional shares at a set price if certain ownership thresholds are met. The rights will expire in three years unless redeemed or exchanged earlier.
Read more →ORMPOramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
Oramed Pharmaceuticals has released a letter to shareholders detailing advancements in its oral insulin program and strategic investments. The company plans to initiate a 60-patient trial in the US to validate its oral insulin formulation. Despite terminating a joint venture, Oramed continues to pursue independent development and has seen significant investment returns.
Read more →ORMPOramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Oramed Pharmaceuticals has announced a strategic investment of $36.9 million in Alpha Tau Medical, acquiring approximately 14.1 million shares. This partnership aims to leverage Oramed's capital markets expertise to support Alpha Tau's innovative cancer therapy, Alpha DaRT. The collaboration includes a three-year service agreement and the appointment of two directors from Oramed to Alpha Tau's board.
Read more →ORMP▲ +7%on this news· ran to +28% by day 3
Oramed Pharmaceuticals Issues Letter to Shareholders
Oramed Pharmaceuticals has issued a letter to shareholders detailing its achievements and future plans. The company is advancing its oral drug delivery technology through a joint venture with Hefei Tianhui Biotech, which is expected to support a Phase 3 clinical trial for oral insulin. Oramed also plans to distribute OraTech stock to shareholders and is evaluating cash dividends to enhance shareholder value.
Read more →ORMP▲ +19.8%on this news
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
Oramed Pharmaceuticals has announced a joint venture, OraTech Pharmaceuticals Inc., with Hefei Tianhui Biotech Co., Ltd. to enhance the development of its oral insulin product, ORMD-0801. This venture aims to leverage advanced manufacturing capabilities and significant financial investment to accelerate commercialization. Oramed shareholders will benefit from a majority equity interest in OraTech, which is set to reinitiate a pivotal Phase 3 clinical trial in the U.S.
Read more →ORMPOramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
Oramed Pharmaceuticals has announced a restructuring of its debt with Scilex Holding Company, involving the execution of agreements for new convertible notes worth $50 million. This restructuring includes a repayment of $22.5 million of existing debt and an anticipated royalty on Scilex's product sales. Oramed's CEO expressed optimism about the potential value of this investment.
Read more →ORMPOramed Letter to Shareholders
Oramed Pharmaceuticals has issued a letter to shareholders outlining recent developments, including a $20 million stock repurchase program and a new Phase 3 oral insulin trial protocol. The company is also finalizing a joint venture with Hefei Tianhui Biotech Co., Ltd. to enhance its oral drug delivery technology. Oramed's CEO emphasizes the company's strong cash position and commitment to advancing its initiatives.
Read more →ORMPOramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock
Oramed Pharmaceuticals Inc. has announced a stock buy-back program authorized by its Board of Directors, allowing for the repurchase of up to $20 million in common stock over the next 12 months. The company will have discretion over the timing and number of shares purchased, depending on market conditions and other factors. This initiative aims to enhance shareholder value, although it does not obligate the company to buy back shares.
Read more →ORMPOramed’s Letter to Shareholders
Oramed Pharmaceuticals has announced a new Phase 3 oral insulin trial in the U.S. following a review of previous trial data that identified responsive patient subpopulations. The company is also forming a joint venture with HTIT, which has completed its own Phase 3 trials in China. Additionally, Oramed has acquired technology from PeriTech to enhance its product offerings.
Read more →ORMPOramed Letter to Shareholders Initiating Phase 3 oral insulin trial in the United States under a new protocol JV with Chinese Partner, HTIT Scilex Senior Secured Note PeriTech Asset Purchase & Strategic Out-licensing
Oramed Pharmaceuticals has provided an update indicating plans to initiate a Phase 3 oral insulin trial in the U.S. under a new protocol, following an analysis showing promising results in specific patient subpopulations. Their partner, HTIT, has successfully completed a Phase 3 trial in China for oral insulin and is investing substantially in commercial production. Additionally, Oramed has formed a joint venture with HTIT to further develop and market their oral insulin technology. Despite facing setbacks with previous trial results, the company's strategy now focuses on leveraging new data and partnerships to enhance shareholder value.
Read more →ORMPOramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company
Oramed Pharmaceuticals has entered into a $101.875 million Senior Secured Note agreement with Scilex Holding Company. This transaction replaces a previous agreement with Sorrento Therapeutics and includes warrants for purchasing Scilex stock. The deal aims to support Scilex's growth while providing Oramed with financial leverage. However, there are risks related to Scilex's debt obligations and stock market fluctuations.
Read more →ORMPOramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company 18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scil
Oramed Pharmaceuticals Inc. has entered into a Securities Purchase Agreement with Scilex Holding Company, resulting in a $101.87 million Senior Secured Promissory Note transaction. This deal allows Scilex to assume a substantial term loan from Sorrento Therapeutics, facilitating a purchase of Scilex's equity interests. As part of the agreement, Oramed received warrants for up to 17 million shares of Scilex, although there are noted risks concerning Scilex's ability to manage the new debt and maintain liquidity.
Read more →ORMPExecution Version NON-BINDING
Oramed Pharmaceuticals has issued a non-binding term sheet outlining proposed transactions involving Scilex Holding Company and Sorrento Therapeutics. The document details Scilex's bid to purchase relevant securities and outlines conditions for potential transactions, including financial obligations and amendments to existing agreements. However, the term sheet is non-binding and subject to approvals from various parties, making it uncertain if the proposed transactions will ultimately be executed.
Read more →ORMPExecution Version Stalking Horse Stock Purchase Term Sheet This term sheet (this " Stalking Horse Term Sheet ") sets forth the principal terms of a proposed equity sale transaction (the " Sale ") between the parties desc
Oramed Pharmaceuticals Inc. has proposed a purchase of equity securities from Sorrento Therapeutics, currently in chapter 11 bankruptcy. The transaction is subject to several conditions, including the approval of the Bankruptcy Court in Texas. The proposed structure involves debtor-in-possession financing, with a total consideration of $105 million, which includes a credit bid and cash payment. The deal's completion hinges on a variety of regulatory approvals and the negotiation of definitive agreements.
Read more →ORMPOramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally
Oramed Pharmaceuticals has signed a term sheet with Hefei Tianhui Biotech Co., Ltd. to establish a joint venture aimed at advancing its oral drug delivery technology. The venture will involve an equal investment from both parties, $60 million from HTIT and $10 million from Oramed, and will focus on Oramed's oral insulin and its Protein Oral Delivery pipeline. The joint venture is intended to fast-track the commercialization of oral insulin in the U.S. and other countries, pending a definitive agreement and necessary approvals.
Read more →ORMPOramed to Present at the 83rd American Diabetes Association Conference
Oramed Pharmaceuticals Inc. has been selected to present an oral abstract at the 83rd American Diabetes Association's Scientific Sessions from June 23-26, 2023, in San Diego. The presentation will focus on the Phase 2 trial results of oral insulin in treating NASH and Type 2 Diabetes, emphasizing its potential benefits in reducing liver fibrosis and fat. This opportunity reflects the company's pioneering work in oral drug delivery solutions. The presentation will also be published on the journal Diabetes® website.
Read more →ORMP▲ +13.2%on this news
Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit
Oramed Pharmaceuticals has announced that its Chief Scientific Officer, Dr. Miriam Kidron, will present at the Novel Therapies for Type 2 Diabetes & Obesity Summit in Boston on May 31, 2023. The presentation will include an overview of the company's oral delivery technology and findings from its recent Phase 3 oral insulin clinical trials. This event marks an important opportunity for Oramed to showcase its advancements in drug delivery solutions.
Read more →ORMP▲ +10.6%on this news· ran to +45% by day 3shared move
Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China
Oramed Pharmaceuticals has announced that its Chinese partner, Hefei Tianhui Biotechnology Co. Ltd. (HTIT), has successfully completed a Phase 3 clinical trial for oral insulin aimed at treating type 2 diabetes. The trial demonstrated significant efficacy in reducing A1C levels among certain patient subgroups. HTIT is now progressing towards regulatory approval, having submitted data to the National Medical Products Administration in China. Oramed's recent analysis of its own Phase 3 trials in the U.S. also revealed promising results that align with these findings.
Read more →ORMP▲ +7.9%on this news· ran to +20% by day 3
Oramed Appoints Ben Shapiro to its Board of Directors
Oramed Pharmaceuticals has appointed Ben Shapiro to its Board of Directors, effective May 1, 2023. Shapiro, co-founder of The Daily Wire and a notable entrepreneur, holds over four percent of Oramed's outstanding stock. His appointment is anticipated to enhance the board's capabilities and bring added value to the company. Oramed's CEO praised Shapiro's talents and operational expertise, expressing optimism about the future of the company and its shareholders.
Read more →ORMP▲ +5.8%on this news
Oramed Pharmaceuticals Issues Shareholder Update
Oramed Pharmaceuticals has announced that it is analyzing data from its discontinued Phase 3 oral insulin trials while also reviewing its overall pipeline. The company is exploring various strategic alternatives to enhance shareholder value, which may include acquisitions, mergers, or other transactions. The management team is actively engaged in evaluating potential opportunities, although no specific transaction or timeline has been set for these strategies.
Read more →ORMP▲ +5.8%on this news· ran to -80% by day 3
Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes
Oramed Pharmaceuticals has announced the disappointing top-line results from its Phase 3 trial of ORMD-0801 for Type 2 Diabetes. The trial failed to meet both the primary and secondary endpoints related to glycemic control and fasting plasma glucose. As a result, Oramed intends to cease its clinical activities involving oral insulin for this condition. The company had previously reported positive findings in prior trials, making this outcome particularly surprising and disappointing.
Read more →ORMPOramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes
Oramed Pharmaceuticals Inc. has been granted a U.S. patent for a combination therapy using oral GLP-1 and insulin to treat diabetes. This patent extends an earlier one granted in May 2022 and strengthens the company's position in developing oral drug delivery methods for therapeutics typically administered via injection. The CEO highlighted that topline data from the first Phase 3 oral insulin trial is anticipated soon. Despite these advancements, potential risks include uncertainties in trial results and market competition.
Read more →ORMPAddressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations December 2022 Oramed Pharmaceuticals Inc. 2022 Safe Harbor 1 Oramed Pharmaceuticals Inc. 2022 This presentation contains forward - looki
Addressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations December 2022 Oramed Pharmaceuticals Inc. 2022 Safe Harbor 1 Oramed Pharmaceuticals Inc. 2022 This presentation contains forward - looking statements. For example, we are using forward - looking
Read more →ORMPOramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism
NEW YORK, Nov. 29, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has publishe
Read more →ORMPOramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH
Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH. Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat, liver stiffness and lipids. Key opinion leaders' discussion hig
Read more →ORMPOramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea
Medicox to Distribute Oramed's Oral Insulin in South Korea, if approved Oramed to Receive Up to $18 Million in Developmental Milestones Oramed to Receive up to 15% Royalties on Gross Sales Large Market Potential: 1 in 7 Koreans Over Age 30 Has Diabetes NEW YORK , Nov. 14, 202
Read more →ORMP▲ +6%on this news· ran to +45% by day 3shared move
Oramed Reports Third Quarter 2022 Financial Results
Oramed Reports Third Quarter 2022 Financial Results NEW YORK, November 10, 2022 - Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms,
Read more →ORMP▼ -6.2%on this news· ran to +19% by day 3shared move
Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH
Webinar scheduled for Thursday, November 17, 2022, at 11:00 a.m. EST Featuring key opinion leader discussion on current treatment landscape NEW YORK, Nov. 9, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmace
Read more →ORMP▼ -7.2%on this news
Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine
Primary and secondary endpoints of safety and immunogenicity met Oral vaccine elicited a potentially protective IgG response with significant seroconversion from baseline Trial shows proof of concept for oral delivery of vaccines using Oravax technology NEW YORK, Oct. 7, 2022
Read more →ORMPOramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate
Primary endpoint met: ORMD-0801 was safe and well tolerated Secondary endpoint met: ORMD-0801 showed clinically meaningful reduction of liver fat from baseline at 12 weeks Strong evidence for treatment of NASH using Oramed's oral insulin NEW YORK, Sept. 13, 2022 /PRNewswire/ -
Read more →ORMP▼ -12.4%on this news
Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will prese
Read more →ORMPOramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial
- ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol - ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023 NEW YORK, July 26, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.o
Read more →ORMP▲ +5.6%on this news
Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference
NEW YORK, July 11, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will present an in-person company overview a
Read more →ORMP▲ +12.7%on this news· ran to +67% by day 3shared move
Oramed Letter to Shareholders $169 Million in Cash and Investments Pivotal Phase 3 Oral Insulin Data Expected January 2023 Phase 2 NASH Data Expected This Quarter Oravax - Oral Vaccine
Oramed Letter to Shareholders NEW YORK, July 7, 2022 - Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Exe
Read more →ORMP▼ -5.4%on this news
Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board
NEW YORK, June 1, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board
Read more →ORMP▼ -13.4%on this news
Oramed to Present at H.C. Wainwright Global Investment Conference
NEW YORK, May 18, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present
Read more →ORMPOramed finaliza la inscripción de pacientes en el estudio ORA-D-013-1
Oramed finaliza la inscripción de pacientes en el estudio central de fase 3 sobre la insulina oral ORA-D-013-1 ORMD-0801 posicionado para ser potencialmente la primera insulina oral aprobada por la FDA para el tratamiento de la diabetes Se ha completado la inscripción de 710 pa
Read more →ORMPOramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1
ORMD-0801 positioned to potentially be the first FDA approved oral insulin for the treatment of diabetes Completed enrollment of 710 patients for the Phase 3 ORA-D-013-1 study Top line data expected in January 2023 NEW YORK, May 3, 2022 /PRNewswire/ -- Oramed Pharmaceuticals I
Read more →ORMPOramed schließt Patientenrekrutierung für die pivotale Phase-3-Studie mit oralem Insulin ORA-D-013-1 ab
ORMD-0801 könnte das erste von der FDA genehmigte orale Insulin für die Behandlung von Diabetes werden Abschluss der Rekrutierung von 710 Patienten für die Phase-III-Studie ORA-D-013-1 Topline-Daten werden im Januar 2023 erwartet NEW YORK, 3. Mai 2022 /PRNewswire/ -- Oramed Ph
Read more →ORMPOramed termine le recrutement des patients dans l
ORMD-0801 positionné pour être potentiellement la première insuline orale approuvée par la FDA pour le traitement du diabète Achèvement du recrutement de 710 patients pour l'étude ORA-D-013-1 de phase 3 Données principales attendues en janvier 2023 NEW YORK, 3 mai 2022 /PRNews
Read more →ORMPOramed Granted NASH Patent in Europe
NEW YORK, April 5, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the European Patent Office has granted the Company the patent titled "
Read more →ORMPOramed Appoints Yadin Rozov to its Board of Directors
NEW YORK, April 4, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Yadin Rozov to its Board of Directors effective April 1,
Read more →ORMPOramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians NEW YORK, March 29, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical...
NEW YORK, March 29, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey commissioned b
Read more →ORMPOramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes
NEW YORK, March 22, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that it will host a webinar with Key Opinion Lead
Read more →ORMP▲ +6.9%on this news
Oramed Completes Patient Enrollment in Phase 2 Oral Insulin NASH Trial
NEW YORK, March 16, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP), (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced it has completed enrollment of all patients in a Phase 2 trial of
Read more →ORMPOramed to Present at Barclays Global Healthcare Conference
NEW YORK, March 10, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present a li
Read more →ORMPOramed Issues Annual Message to Shareholders Oral insulin program continues to advance with topline efficacy data expected in H2 2022 Significant value creation opportunities through oral COVID-19 vaccine program and par
Issues Annual Message to Shareholders Oral insulin program continues to advance with topline efficacy data expected in H2 2022 Significant value creation opportunities through oral COVID-19 vaccine program and partnerships Well positioned to capitalize on opportunities with st
Read more →ORMPOramed Issues Annual Message to Shareholders
NEW YORK, Jan. 12, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidro
Read more →ORMP▼ -8.3%on this news
Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins
NEW YORK, Jan. 5, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the European Patent Office has granted the Company a patent
Read more →ORMPOravax Medical, filiale d
Préachat initial de 10 millions de doses de vaccins oraux avec un accord potentiel pour des commandes supplémentaires d'une valeur de plusieurs centaines de millions de dollars Population prospective d'environ 660 millions de patients dans l'ensemble de l'Association des nations
Read more →ORMPOramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia
NEW YORK, Dec. 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that its subsidiary, Oravax Medical, has signed a
Read more →ORMPOramed-Tochtergesellschaft Oravax Medical unterzeichnet Kooperations- und Kaufvertrag für einen ersten Vorabkauf von 10 Millionen Dosen oraler COVID-19-Impfstoffe mit Tan Thanh Holdings zur Vermarktung in Südostasien
Erster Vorabkauf von 10 Millionen Dosen Schluckimpfstoffen mit der Möglichkeit weiterer Bestellungen im Wert von Hunderten von Millionen Dollar Potenzielle Patientenpopulation von etwa 660 Millionen Menschen im gesamten Verband Südostasiatischer Nationen NEW YORK, 29. Dezember
Read more →ORMPOravax Medical acuerda la compra anticipada inicial de 10 millones de vacunas orales contra la COVID-19
Compra anticipada inicial de 10 millones de dosis de vacunas orales con un posible acuerdo para pedidos adicionales por valor de cientos de millones de dólares estadounidenses Población potencial de pacientes de aproximadamente 660 millones en toda la Asociación de Naciones del
Read more →ORMP▼ -6.8%on this news
Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa
NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that its subsidiary, Oravax Medical Inc. (www.ora-
Read more →ORMPOramed Pharmaceuticals Appoints Chief Legal Officer
NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Netanel Derovan to serve as Chief
Read more →ORMP▼ -11.9%on this newsshared move
Addressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations December 2021 2 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking sta
Addressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations December 2021 2 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking statements are based on the current expectations of the manage
Read more →ORMPOramed to Join MSCI USA Small Cap Index
NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that its common stock will be added to the MSCI US
Read more →ORMPOramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study
NEW YORK, Nov. 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled and randomized over 75% of the
Read more →ORMPOramed to Present at H.C. Wainwright 7th Annual Israel Conference
NEW YORK, November 11, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will p
Read more →ORMP▲ +10.9%on this newsshared move
Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it has closed its pr
Read more →ORMP▼ -12.9%on this newsshared move
Oramed Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
NEW YORK, Nov. 3, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it has entered into
Read more →ORMPOramed Announces Oravax
NEW YORK, Oct. 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its majority-owned subsidiary, Oravax Medical I
Read more →ORMP▲ +8.9%on this news
Oramed to Present at Cantor Fitzgerald Virtual Global Healthcare Conference
NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP), (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will pre
Read more →ORMPOramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral...
NEW YORK, Sept. 15, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled over 50% of patients planned
Read more →ORMPOramed to Present at H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will prese
Read more →ORMPOramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials
NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled and randomized over 25% of th
Read more →ORMP▲ +15.5%on this news
Oramed to Present at Canaccord Genuity
NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Commercial Officer Michael Rabinowitz will
Read more →ORMP▲ +14.7%on this news· ran to +41% by day 3shared move
Oravax to Present Keynote Talk on Oral COVID-19 Vaccine at the Arena International Vaccines Virtual Conference 2021
NEW YORK, Aug. 5, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its majority-owned company Oravax Medical Inc.'s
Read more →ORMP▲ +5.3%on this news· ran to +22% by day 3shared move
Addressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations August 2021 2 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking state
Addressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations August 2021 2 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking statements are based on the current expectations of the manageme
Read more →ORMP▲ +5.6%on this newsshared move
Oramed Pharmaceuticals Appoints Chief Commercial Officer
NEW YORK, July 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Michael Rabinowitz to the newly c
Read more →ORMP▲ +9.7%on this news· ran to +31% by day 3
Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial
NEW YORK, July 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced several updates for its majority-owned company Orava
Read more →ORMPOramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study
NEW YORK, June 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled and randomized over 50% of the 6
Read more →ORMPOramed Issues Letter to Shareholders with Updates on Oral Insulin and COVID-19 Vaccine
NEW YORK, May 25, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following Letter to Shareholders from Chief
Read more →ORMPOramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners
NEW YORK, April 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that CEO Nadav Kidron will be featured in a live we
Read more →ORMPOramed Initiates Second Phase 3 Oral Insulin Study Under the FDA
NEW YORK, March 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in its ORA-D-013
Read more →ORMPFür die Entwicklung neuartiger oraler COVID-19-Impfstoffe gründet Oramed das Joint Venture, Oravax Medical Inc.
In einer präklinischen Studie produzierte der orale Impfstoff nach einer einzigen Dosis erfolgreich Antikörper NEW YORK, 22. März 2021 /PRNewswire/ -- aufgrund des dreifachen Antigen-Targetings ein guter Kandidat für den Schutz gegen COVID-Varianten Implikationen für die poten
Read more →ORMPOramed funda la sociedad conjunta Oravax Medical Inc. para desarrollar nuevas vacunas orales para la COVID-19
La vacuna oral produjo con éxito anticuerpos en un estudio preclínico después de una sola dosis NUEVA YORK, 22 de marzo de 2021 /PRNewswire/ -- Buen candidato para la protección frente a las variantes de COVID debido al enfoque de triple antígeno Implicaciones para posible fac
Read more →ORMPOramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines
NEW YORK, March 19, 2021 /PRNewswire/ -- Good candidate for protection against COVID variants due to triple antigen targeting Implications for potential ease of widescale distribution and administration anytime, anywhere for oral COVID-19 vaccine Efficacy following a single or
Read more →ORMPOramed Pharmaceuticals met au point un vaccin COVID-19 par prise oral, développé par sa joint-venture, Oravax Medical Inc.
Le vaccin oral a fait preuve de succès face à une étude préclinique démontrant la présence d'anticorps suite à l'administration d'une dose unique NEW YORK, 19 mars 2021 /PRNewswire/ -- Candidat idéal pour la protection contre les variantes de la COVID en raison du triple ciblag
Read more →ORMPAddressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations March 2021 2 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking statem
Addressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations March 2021 2 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking statements are based on the current expectations of the managemen
Read more →ORMPOramed Reaches 25% Randomization in World
NEW YORK, March 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled and randomized 25% of the 675 patients
Read more →ORMPOramed to Present at H.C. Wainwright Global Life Sciences Conference 2021
NEW YORK, March 4, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overvie
Read more →ORMPOramed Issues Letter to Shareholders
- Recruiting and Dosing Patients Across Growing Number of U.S. Sites in Phase 3 Oral Insulin Trial - Clinical Advancements in NASH & Leptin - Discussions with Potential Partners Under Way - To view a video message from the CEO, click here NEW YORK, Jan. 27, 2021 /PRNewswire/
Read more →ORMPOramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study
NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery, announced today that randomization of patients in its first Phase 3 study of
Read more →ORMPOramed to Present at H.C. Wainwright BioConnect 2021 Conference
NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview
Read more →ORMPOramed Reports Positive First in Human Data from Oral Leptin Study
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today results from a proof-of-concept study approved by Is
Read more →ORMPOramed Initiates Phase 2 NASH Trial of Oral Insulin
NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in a global trial
Read more →ORMPOramed Initiates Phase 3 Trial of Oral Insulin
NEW YORK, Nov, 24, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in its global Phase 3 tri
Read more →ORMPNobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Nobel Laureate Prof. Avram Hershko and Oramed Chief Sci
Read more →ORMPOramed to Present at H.C. Wainwright 6th Annual Israel Conference
NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overvie
Read more →ORMPOramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 Conference
NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it is presenting a poster at the 2020 American Assoc
Read more →ORMPOramed CEO Nadav Kidron & Premas Biotech to Host Webinar "The Journey of Oral Insulin: Oramed Story" on Wednesday October 28, 2020
NEW YORK, Oct. 27, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will join Premas Biotech's Co-
Read more →ORMPAddressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations October 2020 2 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking stat
Addressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations October 2020 2 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking statements are based on the current expectations of the managem
Read more →ORMPOramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA
NEW YORK, Oct. 16, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following Shareholder Update from Chief Ex
Read more →ORMPOramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting
NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present at the EASD Annual Meeting, held vi
Read more →ORMPOramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral...
NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey conducted for
Read more →ORMPOramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin
NEW YORK, July 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the c
Read more →ORMPOramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin
NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its oral insulin candidate O
Read more →ORMPOramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June
NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present during the 80th American Diabetes Asso
Read more →ORMPOramed Patent in Canada Allowed for Oral Delivery of Proteins
NEW YORK, April 7, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Patent Office has indicated its in
Read more →ORMPOramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19
NEW YORK, April 1, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following Letter to Shareholders from Chie
Read more →ORMPOramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA
NEW YORK, March 19, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced positive feedback from its initial End-of-Phase 2 (
Read more →ORMPOramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million
NEW YORK, Feb. 27, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed" or "Company"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the pricing of an underwritten public offerin
Read more →ORMPOramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock
NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it intends to offer and sell shares of its common stock in an u
Read more →ORMPOramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial
NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Primary endpoints successfully met Results confirm significant clinical benefits of ORMD-0801 at lower dose treatment 0.95% (0.81% placebo adjusted) A1C reduction in patients treated once daily at 8mg Excellent safety profile Paves the
Read more →ORMPOramed to Present at BIO CEO & Investor Conference
NEW YORK, Feb. 4, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview
Read more →ORMPOramed Appoints Dr. Julio Rosenstock to Its Scientific Advisory Board
NEW YORK, Jan. 30, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Dr. Julio Rosenstock to its Scientif
Read more →ORMPOramed Patent in Europe to be Granted for Oral Delivery of Proteins
NEW YORK, Jan. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has indicated it
Read more →ORMPOramed Elects Dr. Alexander Fleming to Scientific Advisory Board
NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the addition of Dr. Alexander Fleming to its Scientific Advisory Boa
Read more →ORMPOramed Appoints Dr. Jay Skyler to Scientific Advisory Board
NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Jay Skyler, MD to its Scientific Adv
Read more →ORMPOramed Appoints Dr. Arie Mayer to Board of Directors
NEW YORK, Dec. 5, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Arie Mayer, Ph.D. to its Board of
Read more →ORMPOramed to Present a Scientific Poster at International Diabetes Federation Congress
NEW YORK, December 2, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it will present a scientific poster at the 2019 I
Read more →ORMPOramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology
NEW YORK, Nov. 21, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Japanese patent for the technology "Proteas
Read more →ORMPOramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event
NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, conducted an investor event and conference call yesterday, November
Read more →ORMPOramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th
NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor event and conference call to review the positive results from t
Read more →ORMPOramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes
NEW YORK, November 12, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced positive results from the initial cohort of the Phase IIb trial e
Read more →ORMPOramed to Present at Ladenburg Thalmann 2019 Healthcare Conference
NEW YORK, Sept. 18, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company's Chief Executive Officer, Nadav K
Read more →ORMPOramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801
NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the treatment of the last patient in the primary cohort of the Phase
Read more →ORMPOramed to Present at Three Upcoming Conferences
NEW YORK, Sept. 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company will present at three conferences i
Read more →ORMPOramed to Present at World Diabetes Congress
NEW YORK, July 10, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Dr. Miriam Kidron, Chief Scientific Officer of
Read more →ORMPOramed Announces Xiaoming Gao Joins Board of Directors
NEW YORK, July 2, 2019 /PRNewswire/ --Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that Mr. Xiaoming Gao is joining its board of directors. Mr. Gao is the Chai
Read more →ORMPOramed Provides Clinical Update with Meaningful Data Expected by Year-End
Completed recruitment and randomization of all patients in the primary cohort of Phase IIb HbA1c trial for oral insulin capsule ORMD-0801, potentially the first commercial oral insulin capsule for the treatment of Type 2 diabetes; results expected in 4Q 2019; following results Or
Read more →ORMPOramed to Present at BIO International Convention
NEW YORK, June 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Mark Hasleton, Vice President Business Devel
Read more →ORMPOramed Completes Patient Recruitment of Phase IIb HbA1c Trial for Oral Insulin Capsule ORMD-0801
NEW YORK, May 21, 2019 /PRNewswire/ -- ORMD-0801 reaches significant milestone on path to potentially be the first commercial oral insulin capsule for the treatment of Type 2 diabetes Close to 300 patients have now been enrolled. 70% of patients have already completed treatment
Read more →ORMPOramed to Present at ThinkEquity Conference
NEW YORK, April 29, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming ThinkEquit
Read more →ORMPOramed to Present at 3rd Annual Clinical Trials Summit
NEW YORK, April 11, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming 3rd Annual
Read more →ORMPOramed Patent Allowed in the U.S. for Oral Exenatide
NEW YORK, April 4, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Methods and
Read more →ORMPOramed to Present at H.C. Wainwright Global Life Sciences Conference
NEW YORK, April 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming H.
Read more →ORMPOramed Patent Allowed in the U.S. for Key Aspect of Its Oral Delivery Technology
NEW YORK, March 28, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Protease I
Read more →ORMPChinese Regulatory Authority [NMPA] Approves IND Application of Oramed
NEW YORK, March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incubator o
Read more →ORMPOramed Initiates Phase I Oral GLP-1 Study Under IND
JERUSALEM, Jan. 22, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has begun recruitment for its Phase 1 pharm
Read more →ORMPOramed Pharmaceuticals
JERUSALEM, Jan. 15, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) We opened the year 2019 with the announcement of our receipt of a $3 million milestone payment from our partners HTIT, thereby increasing our total payments from HTI
Read more →ORMPOramed Receives Additional $3 Million Milestone Payment from HTIT
JERUSALEM, Jan. 9, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received a milestone payment of $3 milli
Read more →ORMPOramed Completes Over 50% Randomization in Its Pivotal 90-Day Clinical Study
NEW YORK, Nov. 13, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully randomized more than 50% of
Read more →ORMPOramed to Present at the Tides Europe 2018 Conference
NEW YORK, Nov. 5, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Tid
Read more →ORMPOramed to Present at Cardiometabolic Health Congress
NEW YORK, Oct. 23, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing two recent Ph
Read more →ORMPOramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH
NEW YORK, Oct. 4, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has enrolled the first patient in an exploratory c
Read more →ORMPOramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule
NEW YORK, Sept. 17, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) ha
Read more →ORMPOramed to Present at the H.C. Wainwright Global Investment Conference
NEW YORK, Aug. 28, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming H.
Read more →ORMPOramed Granted Japanese Patent for GLP-1 Analog Capsule
NEW YORK, July 24, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Japanese Intellectual Property Office has p
Read more →ORMPOramed Announces Closing of $18.1 Million Registered Direct Offering
NEW YORK, July 6, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the closing of its previously-announced registered direct offering with
Read more →ORMPOramed Announces $18.1 Million Registered Direct Offering
NEW YORK, July 3, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has entered into definitive agreements with several healthcare
Read more →ORMPOramed Enrolls First Patient in Its Glucose Clamp Study for Oral Insulin
NEW YORK, June 25, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has enrolled the first patient in its Glucose Cla
Read more →ORMPOramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801
NEW YORK, June 21, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has initiated a food effect study in the U.S
Read more →ORMPOramed to be Added to Russell Microcap® Index
NEW YORK, June 19, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be added to the FTSE Russell Microcap®
Read more →ORMPOramed to Present at the American Diabetes Association 78th Scientific Sessions
NEW YORK, June 12, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that three scientific abstracts will be presented as
Read more →ORMPOramed Patent Allowed in the US for Oral Administration of Proteins
NEW YORK, May 30, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Pr
Read more →ORMPOramed to Present at Conferences in May
NEW YORK, May 7, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will present at three conferences over the nex
Read more →ORMPOramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study for Oral Insulin
NEW YORK, April 23, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has begun screening patients in its 90-day dose-
Read more →ORMPOramed to Present at H.C. Wainwright Annual Global Life Sciences Conference
NEW YORK, March 27, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will be featured as a presenting company at the
Read more →ORMPOramed to Present at Oppenheimer
NEW YORK, March 15, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Oppenheim
Read more →ORMPOramed Adds Two New Members to its Scientific Advisory Board
NEW YORK, Feb. 28, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the additions of Drs. Robert Henry and Jane Reusch t
Read more →ORMPOramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension
JERUSALEM, Feb. 20, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming C
Read more →ORMPOramed to Present at BIO CEO Investor Conference
JERUSALEM, Feb. 6, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BI
Read more →ORMPOramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule
JERUSALEM, Nov. 14, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Israel's Ministry of Health has granted the Company approva
Read more →ORMPOramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins
JERUSALEM, Oct. 31, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the European Patent Office has issued to Oramed a notice of
Read more →ORMPOramed to Present at the Diabetes Technology Meeting
JERUSALEM, October 24, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcomin
Read more →ORMPEndocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by Oramed Scientists
JERUSALEM, Oct. 17, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the publication of a new paper co-authored by Oramed's Chief Sci
Read more →ORMPOramed to Present at the Disruptive Growth Showcase Conference
JERUSALEM, Sept. 25, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 2017 Dis
Read more →ORMPOramed Announces Successful Meeting with FDA for Oral Insulin
JERUSALEM, Sept. 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully concluded its meeting with
Read more →ORMPOramed to Present at the Rodman & Renshaw Global Investment Conference
JERUSALEM, August 29, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming
Read more →ORMPOramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs
JERUSALEM, July 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Simon Bruce MD to the newly created position of Vice President of Medical Affairs. "We are very
Read more →ORMPOramed to Present at BIT
JERUSALEM, July 12, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed's Chief Scientific Officer, will
Read more →ORMPOramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program
JERUSALEM, July 11, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) has agreed to s
Read more →ORMPOramed Announces Dual-Listing on Tel Aviv Stock Exchange
JERUSALEM, July 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received approval from the Israel Securities Authorit
Read more →ORMPOramed Granted Japanese Patent for Combination Insulin and GLP-1 Analog Capsule
JERUSALEM, June 27, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Japanese Intellectual Property Office has publicized it
Read more →ORMPOramed to Present at Conferences Next Week
JERUSALEM, May 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer, Nadav Kidron, will present at three
Read more →ORMPOramed Granted Canadian Patent for GLP-1 Analog Capsule
JERUSALEM, May 9, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Intellectual Property Office has granted Oramed
Read more →ORMPOramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule
JERUSALEM, May 2, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that based on positive preclinical data, the Company is developing
Read more →ORMPOramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule
JERUSALEM, April 20, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has granted the Company a paten
Read more →ORMPJournal of Diabetes Science and Technology Publishes Scientific Paper Authored by Oramed Scientists
JERUSALEM, April 4, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today a new paper co-authored by Oramed's Chief Scientific Officer, Dr
Read more →ORMPOramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017
JERUSALEM, March 22, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed's Chief Scientific Officer, will
Read more →ORMPOramed Appoints Dr. Ronald Law as Chief Strategy Officer
JERUSALEM, March 21, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Ronald Law to the newly created position of Chief Strategy Officer. "We are very pleased to we
Read more →ORMPOramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences
JERUSALEM, Feb. 7, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Inves
Read more →ORMPOramed's ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced it successfully concluded a...
JERUSALEM, Nov. 29, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced it successfully concluded a Phase Ib study of ORMD-0901, the Company's proprietary oral GLP-1 analog. The Phase Ib stud
Read more →ORMPOramed Receives Additional $4 Million Milestone Payment From HTIT
JERUSALEM, October 6, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced it has received an additional milestone payment of $4 million from Hefei Tianhui Incubator of Technologies Co
Read more →ORMPOramed to Present at the Aegis Capital Growth Conference
JERUSALEM, September 19, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming A
Read more →ORMPOramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of Glucose Levels vs Placebo
JERUSALEM, July 28, 2016 /PRNewswire/ -- Statistically Significant Results Across Key Glycemic Endpoints Conference Call Today at 11:00 AM ET Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today reported additiona
Read more →ORMPORA - D - 007 : Randomized, Double - Blind, Placebo - Controlled Study to Assess the Safety and Efficacy of Multiple Oral Bedtime Doses of ORMD - 0801 (Insulin Capsules) in Adult Patients with Type 2 Diabetes Mellitus wh
ORA - D - 007 : Randomized, Double - Blind, Placebo - Controlled Study to Assess the Safety and Efficacy of Multiple Oral Bedtime Doses of ORMD - 0801 (Insulin Capsules) in Adult Patients with Type 2 Diabetes Mellitus who are Inadequately Controlled with Diet and Metformin Presen
Read more →ORMPOramed Appoints Dr. Roy Eldor as Chief Medical Director
JERUSALEM, July 26, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Roy Eldor MD PhD to the newly created position of Chief Medical Director. "We are very
Read more →ORMPOramed Announces $6.5 Million Milestone Payment from HTIT
JERUSALEM, June 21, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced that Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT) is transferring a $6.5 million milestone payment from the
Read more →ORMPOramed to Present at the American Diabetes Association 76th Scientific Sessions
JERUSALEM, June 9, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing a study performed
Read more →ORMPAddressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations May 2016 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking statements
Addressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations May 2016 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking statements are based on the current expectations of the management of
Read more →ORMPOramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study
JERUSALEM, May 18, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), today announced positive top-line results from its Phase IIb study, designed to evaluate the safety and efficacy of its oral insulin capsule (ORMD-0801) in patients with type 2 diabetes. The stud
Read more →ORMPOramed to Present at Oppenheimer Annual Israeli Conference
JERUSALEM, May 16, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Oppenhe
Read more →ORMPOramed Patent Being Granted in China for Oral Administration of Proteins
JERUSALEM, May 11, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that an official Notification of Granting Patent Right was issued for the Company's patent for its invention tit
Read more →ORMPOramed to Present at PIONEERS 2016, Presented by Joseph Gunnar
JERUSALEM, April 28, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming PIONE
Read more →ORMPOramed Receives Patent Term Adjustment Extending the Term of Its U.S. Patent
JERUSALEM, April 12, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Patent and Trademark Office (PTO) has iss
Read more →ORMPOramed Completes Phase IIb Oral Insulin Study
JERUSALEM, April 5, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that all follow-up visits in the Company's Phase IIb stu
Read more →ORMPOramed Patent Granted in India for Oral Administration of Proteins
JERUSALEM, March 29, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Prot
Read more →ORMPOramed to Present at the BIO CEO & Investor Conference
JERUSALEM, February 4, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 18t
Read more →ORMPAddressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations January 2016 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking statem
Addressing the Multibillion - Dollar Injectable Drug Markets with Oral Formulations January 2016 Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking statements are based on the current expectations of the managemen
Read more →ORMPOramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in China
JERUSALEM, December 29, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced the closing of its previously-announced license and investment deal with Hefei Tianhui Incubation of Techno
Read more →ORMPOramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China
From left to right: Prof. Avram Hershko, Oramed Scientific Advisory Board; Mr. Nadav Kidron, Oramed CEO; Mr. Bin Zhou, Sinopharm Vice General President; Mr. Xiaoming Gao, HTIT Chairman [photo: Maoz Vaystooch. editorial use only/courtesy Oramed.] JERUSALEM, Nov. 30, 2015 /PRNewsw
Read more →ORMPOramed Completes Randomization of Over 50% of Patients in Phase IIb Oral Insulin Study
JERUSALEM, September 9, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that 98 patients have already been enrolled in the C
Read more →ORMPSinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China
JERUSALEM, July 7, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has signed a non-binding Letter of Intent (LoI) f
Read more →ORMPNasdaq: ORMP July 2015 Corporate Presentation Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking statements are based on the current expectations of the m
Nasdaq: ORMP July 2015 Corporate Presentation Safe Harbor Certain statements contained in this material are forward - looking statements . These forward - looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of fa
Read more →ORMPOramed Enrolls First Patient in its Phase IIb Oral Insulin Study
JERUSALEM, June 30, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical Company focused on the development of oral drug delivery systems, announced today that the first patient has been screened in the Company'
Read more →ORMPOramed Granted Patent in Russia for Oral Administration of GLP-1
JERUSALEM, June 16, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the Russian Federal Service for Intellectual Property has granted the Company a patent for its invention,
Read more →ORMPOramed Announces Closing of $5.36 Million Registered Direct Offering
JERUSALEM, June 11, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), a developer of oral drug delivery systems, today announced the closing of its previously-announced registered direct placement with institutional investors. Oramed has sold $5.36 million of shar
Read more →ORMPOramed to Raise $5.36 Million in Registered Direct Offering
JERUSALEM, June 5, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced that it entered into purchase agreements with several institutional investors for a registered direct placement.
Read more →ORMPOramed to Present at the American Diabetes Association 75th Scientific Sessions
JERUSALEM, June 2, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing studies performed
Read more →ORMPOramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study
JERUSALEM, May 26, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has submitted the study protocol for the company'
Read more →ORMPOramed to Present at Upcoming Conferences
JERUSALEM, May 5, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the company will present at the following conferences
Read more →ORMPOramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter
JERUSALEM, April 28, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com) Dear Friends, Shareholders and Associates, I am very excited to announce that we are on the threshold of initiating our much-awaited Phase IIb clinical trial for oral i
Read more →ORMPOramed to Present at the GTC Diabetes Summit
JERUSALEM, April 20, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the company will participate in the upcoming Annua
Read more →ORMPOramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin
JERUSALEM, April 1, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the first patient has been enrolled in its Glucose Clamp
Read more →ORMPOramed to Present at the ROTH Conference
JERUSALEM, March 4, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the company will participate in the upcoming 27th A
Read more →ORMPOramed to Present Poster at the GTC Protease Inhibitors in Drug Discovery Conference
JERUSALEM, February 19, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract titled "Protease Inhibito
Read more →ORMPOramed Pharmaceuticals Inc. Issues Letter to Shareholders
JERUSALEM, January 28, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), Dear Friends, Shareholders and Associates, As we recently entered into the New Year, I thought this would be a good opportunity to reflect on the achievements of thi
Read more →ORMPOramed Granted Patent in Israel for Oral Administration of GLP-1
JERUSALEM, January 16, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Israel Patent Office has granted the Company
Read more →ORMPOramed Closes $5 Million Investment From Guangxi Wuzhou Pharmaceutical Company
JERUSALEM, Israel, December 3, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, today announced that it has received $5 million in connection with the definitive agreement with Guangxi Wuzhou Pharmaceutical Co., Ltd.,
Read more →ORMPOramed Pharmaceuticals at LD MICRO "Main Event" Micro-Cap Growth Conference on December 2, 2014
JERUSALEM, December 1, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Company management will participate in the upc
Read more →ORMPOramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes
JERUSALEM, October 31, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)(http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announces that the company will host a conference call to discuss th
Read more →ORMPOramed to Present at the FireRock Annual Micro-Cap Conference
JERUSALEM, October 24, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company's CEO, Nadav Kidron will present a
Read more →ORMPOramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes
JERUSALEM, October 22, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reported positive top-line clinical results from its Phase I
Read more →ORMPOramed to Present at Family Office & Wealth Management Conference
JERUSALEM, September 15, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company's CEO, Nadav Kidron will present at D
Read more →ORMPOramed Granted Patent in Spain for Oral Administration of Insulin
JERUSALEM, August 19, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Spain h
Read more →ORMPOramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes
JERUSALEM, August 7, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reports that the last patient has completed treatment in its Phas
Read more →ORMPOramed Pharmaceuticals to Present at the BIO International Convention in San Diego
JERUSALEM, June 23, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chief Executive Officer, Nadav Kidron, will p
Read more →ORMPOramed Pharmaceuticals Added to the Morgan Stanley Capital International (MSCI) MicroCap Index
JERUSALEM, May 29, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has been added to the Morgan Stanley Capital In
Read more →ORMPOramed to Present at Jefferies Global Healthcare Conference on June 2 in New York City
JERUSALEM, May 27, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Nadav Kidron, the Company's Chief Executive Officer, will
Read more →ORMPOramed Pharmaceuticals to Present at the IATI Israel Innovation Conference in Tel Aviv
JERUSALEM, May 19, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a clinical-stage developer of oral delivery systems, announced today that Josh Hexter, Oramed's Chief Operating Officer and Vice President of Business Development, will present a corporate over
Read more →ORMPOramed to Present Poster on its Oral Insulin Capsule at the Yale Diabetes Symposium
JERUSALEM, May 13, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a poster on the Company's orally ingestible insuli
Read more →ORMPOramed Granted Patent in Hong Kong for Oral Administration of Insulin
JERUSALEM, April 10, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Hong Kong has gr
Read more →ORMPOramed Pharmaceuticals Announces First Patient Enrolled in a US Phase 2a Trial for ORMD-0801 in Treatment of Type 1 Diabetes
JERUSALEM, March 27, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the first patient has been enrolled in its U.S.
Read more →ORMPOramed Granted its 3rd Patent in Australia for Oral Administration of Exenatide
JERUSALEM, March 11, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that IP Australia, the Australian government's patent office,
Read more →ORMPOramed to Present Results from its Phase 2a FDA Trial with ORMD-0801 at the 2014 Diabetes Summit on April 24, 2014
JERUSALEM, March 3, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its r
Read more →ORMPOramed Announces Successful FDA Phase 2a Clinical Trial Results
JERUSALEM, Jan. 30, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was co
Read more →ORMPOramed to Announce Results of its Phase 2a Clinical Trial for Oral Insulin on January 30th at the Tel Aviv Stock Exchange
JERUSALEM, January 27, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it will announce the results of its Phase 2a clinical trial for the company's ORMD-0801 oral insulin
Read more →ORMPOramed Receives Patent Allowance in Israel and Australia for Platform Technology in Oral Delivery of Proteins
JERUSALEM, January 2, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has received Notices of Allowance from the Israel and Australian Patent Offices. The patent entitle
Read more →ORMPOramed to Raise $15,800,000 in Registered Direct Offering
JERUSALEM, Dec. 24, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, today announced that it has entered into definitive agreements with investors to purchase an aggregate of 1,580,000 shares of common stock at a price
Read more →ORMPOramed Announces Successful Results from Ex-US Pharmacokinetic Study of its Oral Insulin for the Treatment of Type 1 Diabetes
JERUSALEM, Dec. 20, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today successful results in a clinical trial testing the pharmacokin
Read more →ORMPOramed Receives Allowance on its Core Oral GLP-1 Technology Patent in Israel
JERUSALEM, December 10, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM:ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received allowance for a key patent fro
Read more →ORMPOramed Receives Patent in the European Union for the Oral Delivery of Insulin
JERUSALEM, Nov. 19, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that the European Patent Office has allowed the Company's patent for its invention, titled "Methods and Compositions
Read more →ORMPOramed Announces Last Patient Out in Phase 2a FDA Trial of its ORMD-0801 Oral Insulin Capsule
JERUSALEM, November 12, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the last patient has left the clinic from its
Read more →ORMPOramed Granted Patents in Japan and Canada for its POD™ Technology for the Oral Delivery of Proteins
JERUSALEM, October 3, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has received two additional patent approvals for its platform Protein Oral Delivery (POD™) technolo
Read more →ORMPOramed to Participate in Barclays
JERUSALEM, September 25, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been invited to participate in an exclusive Israeli Biotech Corporate Day, hosted by Barclay
Read more →ORMPOramed's Platform Technology in Oral Delivery of Proteins Receives Patent in Russia Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been...
JERUSALEM, September 17, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been granted a patent from Russia's Federal Service for Intellectual Property, Patents and T
Read more →ORMPOramed Granted Patent in China for its Platform Technology in Oral Delivery of Proteins
JERUSALEM, September 10, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has received approval for a key patent from the State Intellectual Property Office of the People
Read more →ORMPOramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes
JERUSALEM, September 3, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has submitted a pre-Investigational New Drug (pre-IND) package to the U.S. Food and Drug Administ
Read more →ORMPOramed Initiates Patient Recruitment for a New Clinical Trial in Israel of its Oral Insulin Drug ORMD-0801 in the Treatment of Type 1 Diabetes
JERUSALEM, August 21, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has initiated patient recruitment for a new clinical trial of its orally ingestible insulin capsule
Read more →ORMPOramed Submits Pre-IND Meeting Request to FDA for its Oral Exenatide Capsule ORMD-0901
JERUSALEM, July 30, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that it submitted a pre-Investigational New Drug (pre-IND) meeting request to the U.S. Food and Drug Administration (
Read more →ORMPOramed to Raise $4,600,000 in Registered Direct Offering
JERUSALEM, July 10, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, today announced it has entered into definitive agreements with investors to purchase an aggregate of 657,144 shares of common stock at a price of $7.
Read more →ORMPOramed Enrolls First Patient in its Phase 2a U.S. Oral Insulin Clinical Trial
JERUSALEM, July 8, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the first patient has been enrolled in a Phase 2a trial of ORMD-0801, an orally ingestible insulin capsul
Read more →ORMPOramed to Present at the 8th Annual JMP Securities Healthcare Conference in New York City
JERUSALEM, July 2, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the company's CEO, Nadav Kidron, will present at the JMP Securities 2013 Healthcare Conference on Tuesday
Read more →ORMPOramed Pharmaceuticals to Present Findings on Oral Insulin to the American Diabetes Association
JERUSALEM, June 21, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it will be presenting its abstract titled, "Dose response to oral insulin capsules in fasting, healthy s
Read more →ORMPOramed Pharmaceuticals Announces Withdrawal of Proposed Underwritten Public Offering
JERUSALEM, June 21, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has withdrawn the previously announced proposed underwritten public offering of its common stock due
Read more →ORMPOramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel
JERUSALEM, June 10, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a clinical-stage developer of oral delivery systems, announced today that it has been invited to present at the 12th National Life Science & Technology Week IATI-BioMed Conference taking place
Read more →ORMPOramed Selected to Present at the 81st European Atherosclerosis Society Congress in Lyon, France, June 2-5, 2013
JERUSALEM, June 3, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that its abstract, titled "Decreased CRP levels in response to a six-week, once-daily oral insulin regimen" ha
Read more →ORMPOramed Pharmaceuticals Awarded Grant by the Office of the Chief Scientist of Israel
JERUSALEM, May 30, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that its wholly owned Israeli subsidiary, Oramed Ltd., was awarded a government grant from the Office of the C
Read more →ORMPOramed CEO to Present at New York Biotechnology Association and The Israel Conference
JERUSALEM, May 28, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the company's CEO, Nadav Kidron, has been invited to be a speaker at two key events in New York and Los A
Read more →ORMPOramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
JERUSALEM, May 17, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug a
Read more →ORMPClinical Results for Oramed
JERUSALEM, May 1, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral delivery systems of drugs currently administered by injection, announced today that its article titled, "Glucose-reducing effect of the ORMD-0801 oral
Read more →ORMPOramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
JERUSALEM, April 29, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management
Read more →ORMPOramed CEO to be Panelist at BIO International Convention Breakout Session on Israel Becoming Biotech Leader
JERUSALEM, April 22, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral delivery systems, announced today that the Company's CEO Nadav Kidron has been invited to be a panelist for a breakouts session at the BIO Internat
Read more →ORMPOramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
JERUSALEM, April 18, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral delivery systems, announced today that its abstract, titled "Oral insulin may be effective in lowering hepatic insulin resistance and inflammation
Read more →ORMPOramed Pharmaceuticals Appoints New Chief Operating Officer and VP of Business Development
JERUSALEM, April 16, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced a key addition to its executive leadership team with the appointment of Joshua Hexter as Chief Operating Off
Read more →ORMPOramed Submits New IND Application for Oral Insulin Trial in the US
JERUSALEM, April 11, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has submitted a new Investigational New Drug (IND) application with the U.S. Food and Drug Administr
Read more →ORMPOramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
JERUSALEM, April 3, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the Japanese Patent Office. The patent, titled "Methods and C
Read more →ORMPOramed Pharmaceuticals Selected to Present at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, IL, June 21-25, 2013
JERUSALEM, March 21, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that its abstract, titled "Dose response to oral insulin capsules in fasting, healthy subjects," has been se
Read more →ORMPOramed Pharmaceuticals to Present at the 4th Annual Drug Delivery & Formulation Summit in Berlin
JERUSALEM, February 18, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral delivery systems, announced today that Dr. Ehud Arbit, Oramed's Director of Research & Development, will be presenting at the 4th Annual Drug Deli
Read more →ORMPOramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
JERUSALEM, February 14, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigat
Read more →ORMPOramed Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
NEW YORK, Feb. 11, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that their February 7th RetailInvestorConferences.com presentation is now available for on-demand viewing. LINK:
Read more →ORMPShares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market
JERUSALEM, February 7, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTCQB: ORMPD), a developer of oral drug delivery systems, announced today that NASDAQ has approved the company's application to list its shares of common stock on the NASDAQ Capital Market. The company's sh
Read more →ORMPOramed Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
NEW YORK, Feb. 5, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTC:ORMPD) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that Nadav Kidron, Chief Executive Officer & Director, will present at RetailInvestorConferences.com. DATE: February
Read more →ORMPOramed Pharmaceuticals Announces Reverse Stock Split
JERUSALEM, January 22, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTCQB:ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that its previously announced one for twelve reverse stock split has become effective. As of the open of busin
Read more →ORMPOramed Pharmaceuticals Files Investigational New Drug Application with the FDA for Oral Insulin
JERUSALEM, January 7, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTCBB:ORMP.OB) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (
Read more →ORMPOramed Pharmaceuticals Completes $5.6 Million Funding to Advance Clinical Trials
JERUSALEM, December 11, 2012 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTCBB:ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has completed a capital raise of $4,973,075, net of finder's fee, priced at $0.37 per unit. Each unit
Read more →ORMPOramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
JERUSALEM, November 7, 2012 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP; www.oramed.com), a developer of oral delivery systems, announced today that results of a study performed using its oral insulin formulation, ORMD-0801, have been accepted for presentation at th
Read more →ORMPFormer Johnson & Johnson and Bausch & Lomb Executive, Gerald Ostrov, Joins Oramed Pharmaceuticals
JERUSALEM, October 18, 2012 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTCBB:ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that Gerald Ostrov, former top executive of Johnson & Johnson and Bausch & Lomb, joined its board as Director.
Read more →ORMPOramed Pharmaceuticals to Collaborate With Leading Contract Research Organization Medpace for Phase II FDA Trial on Oral Insulin
JERUSALEM, October 3, 2012 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTCBB:ORMP.OB) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that its subsidiary, Oramed Ltd., has signed an agreement with Medpace, Inc. to retain Medpace as a Clinical
Read more →ORMPOramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
JERUSALEM, July 11, 2012 /PRNewswire/ -- Announcing its third patent approval since the beginning of the calendar year, Oramed Pharmaceuticals Inc. (OTCBB:ORMP.OB) (www . oramed . com), a developer of oral drug delivery systems, announced today that its patent, titled "Methods a
Read more →ORMPOramed Pharmaceuticals Granted Core Technology Patent in New Zealand
JERUSALEM, May 29, 2012 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the New Zealand Patent Office. The patent, entitled "Methods
Read more →ORMPOramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
JERUSALEM, Israel, May 21, 2012 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), a developer of oral delivery systems, announced today that it was chosen to present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference taking place in Israel on
Read more →ORMPOramed Pharmaceuticals Announces Educational Lecture at the National University Hospital in Singapore
JERUSALEM, February 7, 2012 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that Dr Miriam Kidron, Oramed's Chief Medical and Technology Officer, will be delivering a lecture at the Natio
Read more →ORMPOramed Pharmaceuticals Granted Australian Patent for Important Part of the Company
JERUSALEM, January 24, 2012 /PRNewswire/ -- Marking a major milestone for the Company, Oramed Pharmaceuticals Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the Australian P
Read more →ORMPOramed Pharmaceuticals Files US Patent Application for Combination Oral Treatment of Diabetes
JERUSALEM, January 10, 2012 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTCBB:ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a co
Read more →ORMPOramed Pharmaceuticals Chosen to Present at the Diabetes Technology Meeting (October 27-29, 2011; San Francisco, CA)
JERUSALEM, October 25, 2011 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that its work entitled "Evaluation of the Safety and Efficacy of Two Oral Insulin Formulations in Healthy
Read more →ORMPOramed Pharmaceuticals Announces Successful Phase 1 Clinical Trial Results for EnteraBio
JERUSALEM, September 27, 2011 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTC BB: ORMP) (http://www.oramed.com), a developer of oral delivery systems, announced that EnteraBio Ltd. recently reported successful Phase 1 clinical trial results. The Phase 1 data supports the contin
Read more →ORMPOramed Pharmaceuticals Chosen to Present at the 8th Annual Israel Strategic Partner and Venture Conference on September 22, 2011
JERUSALEM, September 15, 2011 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTC BB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that Ehud Arbit, M.D., the Director of R&D at Oramed, is scheduled to present at the 8th Annual Israel Strat
Read more →ORMPOramed Pharmaceuticals to Present at Rodman & Renshaw 13th Annual Global Investment Conference
JERUSALEM, September 8, 2011 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTC BB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that Roy Eldor, M.D., the Director of Medical Affairs at Oramed, is scheduled to present at the Rodman & Rens
Read more →ORMPOramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
JERUSALEM, Israel, June 22, 2011 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), a biotech company with a novel platform technology for the oral delivery of drugs currently only available via injection, announced today that Dr. Michael Berelowitz, M.D., has been ap
Read more →ORMPOramed Pharmaceuticals to Present at The 1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CHODy), China 2011
JERUSALEM, May 18, 2011 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that it was chosen to present at The 1st Asia Pacific Congress on Controversies to Consensus in Diabetes,
Read more →ORMPOramed Pharmaceuticals to Present at The 1 st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CHODy), China 2011 Oramed to Present on Friday
Oramed Pharmaceuticals to Present at The 1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CHODy), China 2011 Oramed to Present on Friday June 3, 2011 JERUSALEM, Israel - May 18, 2011 - Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB)
Read more →ORMPUnassociated Document Oramed Pharmaceuticals to Present at the 10th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2011 Oramed to Present on Tuesday
Oramed Pharmaceuticals to Present at the 10th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2011 Oramed to Present on Tuesday, May 24, 2011 at 12:50 p.m. (IDT) JERUSALEM, Israel - May 11, 2011 - Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB);www.oramed.
Read more →ORMPOramed Pharmaceuticals to Present at the 10th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2011
JERUSALEM, May 11, 2011 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that it was chosen to present at the 10th National Life Science & Technology Week ILSI-BIOMED Conference,
Read more →ORMPUnassociated Document Oramed Pharmaceuticals Announces Completion of $3.4 Million Private Placement Round Jerusalem, Israel
Oramed Pharmaceuticals Announces Completion of $3.4 Million Private Placement Round Jerusalem, Israel - March 9, 2011 - Oramed Pharmaceuticals Inc. (OTC: ORMP; www.oramed.com), a developer of oral delivery systems, announced today that it has completed a capital raise of $3,356
Read more →ORMPUnassociated Document Oramed Successfully Completes Toxicity Study for ORMD-0801 Jerusalem, Israel
Oramed Successfully Completes Toxicity Study for ORMD-0801 Jerusalem, Israel -- March 23, 2011 -- Oramed Pharmaceuticals Inc. (OTC: ORMP), a developer of oral delivery systems, announced today that it has successfully completed a comprehensive toxicity study for its flagship ora
Read more →ORMPOramed Successfully Completes Toxicity Study for ORMD-0801
JERUSALEM, March 23, 2011 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTC: ORMP), a developer of oral delivery systems, announced today that it has successfully completed a comprehensive toxicity study for its flagship oral insulin capsule, ORMD-0801. The study was com
Read more →ORMPOramed Pharmaceuticals Announces Completion of $3.4 Million Private Placement Round
JERUSALEM, March 9, 2011 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTC: ORMP) (http://www.oramed.com), a developer of oral delivery systems, announced today that it has completed a capital raise of $3,356,000 in a private placement of 10,487,500 shares of its common
Read more →ORMPUnassociated Document Oramed Pharmaceuticals Sells its Stake in Entera Bio for $1.15 Million; Buyer Also to Invest $250,000 in Oramed Jerusalem, Israel
Oramed Pharmaceuticals Sells its Stake in Entera Bio for $1.15 Million; Buyer Also to Invest $250,000 in Oramed Jerusalem, Israel -- February 28, 2011 -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP), a developer of oral drug delivery systems, announced today that its subsidiary Ora
Read more →ORMPOramed Pharmaceuticals Sells its Stake in Entera Bio for $1.15 Million; Buyer Also to Invest $250,000 in Oramed
JERUSALEM, February 28, 2011 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP), a developer of oral drug delivery systems, announced today that its subsidiary Oramed Ltd. entered into a Share Purchase Agreement with D.N.A Biomedical Solutions Ltd. (formerly Lase
Read more →ORMPOramed Chosen to Lecture at the Fourth International Conference on Advanced Technologies and Treatments for Diabetes in London, England
Chosen to Lecture at the Fourth International Conference on Technologies and Treatments for Diabetes in London, Israel - February 15, 2011- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (www.oramed.com), a developer of alternative drug delivery systems, announced today that i
Read more →ORMPPharmaceuticals was Awarded a NIS 2.9 million Grant from the Israeli Office of
Pharmaceuticals was Awarded a NIS 2.9 million Grant from the Israeli Office of Israel - December 23, 2010 Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, today reported that its wholly owned Israeli subsidiary, Oramed
Read more →ORMPOramed Pharmaceuticals Announces Publication in the Journal of Diabetes Science and Technology Results describe preclinical trials demonstrating retained GLP-1 analog activity when delivered with Oramed's oral drug deliv
Pharmaceuticals Announces in the Journal of Diabetes describe preclinical trials demonstrating retained GLP-1 analog activity when delivered with Oramed's oral drug delivery formulations Israel - December 1, 2010 - Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB; www.oramed.com)
Read more →ORMPUnassociated Document Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda
Pharmaceuticals Presents Results of its Phase IIb Clinical Trial Diabetes Technology Meeting 2010 in Bethesda, MD. Israel -November 15, 2010 - Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB; www.oramed.com), a developer of oral drug delivery systems, presented the results of its
Read more →ORMPOramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
JERUSALEM, November 15, 2010 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, presented the results of its recently completed Phase IIb trial. The multicenter, placebo-controlled, randomized, d
Read more →ORMPOramed Pharmaceuticals to Present Results of an Oral Insulin Administration Study at the Tenth Annual Meeting of the Diabetes Technology Society (November 11-13, 2010; Bethesda, MD)
JERUSALEM, October 26, 2010 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that its work entitled "Extended exposure to an oral insulin formulation yields decreased insulin
Read more →ORMPUnassociated Document Oramed Pharmaceuticals to Present Results of an Oral Insulin Administration Study at the Tenth Annual Meeting of the Diabetes Technology Society (November 11-13, 2010; Bethesda, MD)
Pharmaceuticals to Present Results of an Oral Insulin Study at the Tenth Annual Meeting of the Diabetes Society (November 11-13, 2010; Bethesda, MD) Israel , October 26, 2010 - Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB; www.oramed.com), a developer of oral drug delivery sys
Read more →ORMPOramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule Proof of Concept Study for a New Indication of Oral Insulin Capsule for Type 1 Diabetics
Pharmaceuticals Announces Successful Results of a Novel Clinical Study of its Flagship Oral Insulin Capsule Concept Study for a New Indication of Oral Insulin Capsule for Type Israel - September 14, 2010 - Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) announced today successfu
Read more →ORMPUnassociated Document This presentation may contain forward-looking statements, including statements regarding the intent, belief or current expectations of Oramed Pharmaceuticals Inc. and affiliates about the market, bu
presentation may contain forward-looking statements, including statements regarding the intent, belief or current expectations of Oramed Pharmaceuticals Inc. and affiliates about the market, business, properties, financial condition and results of operations of our 50% indirec
Read more →ORMPOramed Pharmaceuticals and sanofi-aventis Enter into an Agreement for the Insulin supply of Oramed's Oral Insulin Capsules.
Pharmaceuticals and sanofi-aventis Enter into an Agreement for the Insulin supply of Oramed's Oral Insulin Capsules. Israel, July 7, 2010- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, today announced that Oramed e
Read more →ORMPUnassociated Document Oramed Pharmaceuticals to present at the 70 th Scientific Sessions of the American Diabetes Association Results of first exposure of Type I diabetes patients to Oramed's oral insulin and of a first-
Pharmaceuticals to present at the 70th Scientific Sessions of American Diabetes Association of first exposure of Type I diabetes patients to Oramed's oral insulin and of a first-in-humans study with its oral GLP-1 analog IL - June 28, 2010 - Oramed Pharmaceuticals Inc. (OTCB
Read more →ORMPUnassociated Document Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70 th Scientific Sessions of the American Diabetes Association in Orlando FL, June 25-29, 2010 Jerusalem, IL
Pharmaceuticals was Chosen to Present Two Abstracts at Scientific Sessions of the American Diabetes Association in FL, June 25-29, 2010 IL - June 15, 2010 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of alternative drug delivery systems,
Read more →ORMPOramed Pharmaceuticals to Present at the 9th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2010 Oramed to present on Wednesday, June 16 th at 11:50 a.m. (IDT)
Pharmaceuticals to Present at the 9th National Life Science & Week ILSI -BIOMED Conference, Israel 2010 to present on Wednesday, June 16th at Israel - June 8, 2010 - Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB); www.oramed.com), a developer of oral delivery systems, today ann
Read more →ORMPOramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. Jerusalem, Israel
Pharmaceuticals Forms Joint Venture - Israel - June 2, 2010 - Oramed Pharmaceuticals Inc. (OTCBB: ORMP), a developer of oral drug delivery systems, announced today that its subsidiary Oramed Ltd. entered into a joint venture agreement with Laser Detect Systems Detect"), an Is
Read more →ORMPOramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism Study data shows ORMD-0801 resulted in glucose and c-peptide reduction
Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism data shows ORMD-0801 resulted in glucose and c-peptide reduction Israel - May 26, 2010- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www
Read more →ORMPUnassociated Document Oramed Pharmaceuticals announces that Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
Pharmaceuticals announces that Dr. Michael Berelowitz, Senior Vice at Pfizer, Joins its Board of Directors Israel, May 18, 2010-- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) announced that Dr. Michael Berelowitz, MD, joins Oramed Pharmaceuticals' Board of Directors. Dr. Bere
Read more →ORMPOramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients ORMD-0801 Proves Safe and Tolerable in Type 2 Diabetes Subjects
Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients Proves Safe and Tolerable in Type 2 Diabetes Subjects Israel - May 6, 2010- Oramed Pharmaceuticals Inc. (OTCBB: ORMP), a developer of alternative drug delivery systems
Read more →ORMPOramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D. Dr. Amatruda is the former Senior Vice President and Franchise Head of the Diabetes and Obesity Unit at Merck & Co.
Pharmaceuticals Expands Scientific Advisory Board the Appointment of John Amatruda, M.D. Amatruda is the former Senior Vice President and Franchise Head of the Diabetes and Obesity Unit at Merck & Co. Israel - February 16, 2010 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB;
Read more →ORMPUnassociated Document Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to at the Third International Conference on Advanced and Treatments for Diabetes in Basel, Switzerland Israel - February 10, 2010- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (www.oramed.com), a developer of alternative
Read more →ORMPUnassociated Document Oramed Pharmaceuticals Announces Completion of Patient Enrollment for Pivotal Phase 2B Clinical Trials of ORMD-0801 Key Trial for Oral Insulin with E xpect ed R esults at the End of Q1 o f 2010 JERU
Oramed Pharmaceuticals Announces Completion of Patient Enrollment for Pivotal Phase 2B Clinical Trials of Key Trial for Oral Insulin with Expected Results at the End of Q1 of 2010 JERUSALEM, Israel-January 19, 2009-- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) announced toda
Read more →ORMPOramed Pharmaceuticals Announces Filing of Two Registration Statements
Pharmaceuticals Announces of Two Registration Statements JERUSALEM, Israel - January 11, 2010 - Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), a developer of alternative drug delivery systems, today announced that it has filed two registration statements on Form S-1 with the
Read more →ORMPDear Shareholder: As we are about to begin 2010, I would like to take the opportunity to look back on the past year and note the progress that Oramed has made, and look at what is expected in the near future. Last year,
we are about to begin 2010, I would like to take the opportunity to look back on the past year and note the progress that Oramed has made, and look at what is expected in the near future. Last year, beyond the actual clinical trials, Oramed was chosen to present at a number of
Read more →ORMPUnassociated Document Oramed's Dr. Roy Eldor was Chosen to Lecture at the First International Conference held by the Bildirici Center for Diabetes Care Research in Israel.
Dr. Roy Eldor was Chosen to Lecture at the First International held by the Bildirici Center for Diabetes Care Research in Israel. Israel - December 21, 2009- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of alternative drug delivery systems
Read more →ORMPUnassociated Document Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Society's Ninth Annual Meeting (November 5-7, 2008; San Francisco, Califor
Pharmaceuticals was Chosen to Present Results of a GLP-1 Oral Administration Study at the Diabetes Technology Society's Annual Meeting (November 5-7, 2008; San Francisco, California) Israel - October 20, 2009 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; www.oramed.com), a
Read more →ORMPUnassociated Document Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog ORMD 0901 is being developed as an oral dosage form of a GLP-1 Analog aimed at improving glycemic control in adults wit
Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog is being developed as an oral dosage form of a GLP-1 Analog improving glycemic control in adults with type 2 diabetes. Israel - September 9, 2009 - Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), a develop
Read more →ORMPOramed Pharmaceuticals to Present at Rodman & Renshaw 11 th Annual Healthcare Conference
Pharmaceuticals to Present at Rodman & Renshaw 11th Healthcare Conference Israel - September 3, 2009 - Oramed Pharmaceuticals Inc. (OTC BB: ORMP.OB) (http://www.oramed.com), a developer of alternative drug delivery systems, announced today that Nadav Kidron, its Chief Executi
Read more →ORMPUnassociated Document Frost and Sullivan Honors Oramed Pharmaceuticals with the 2009 European Oral Drug Delivery Technology Innovation Award JERUSALEM, Israel, August 25 /PRNewsw ir e-F ir stCall/ -- Oramed Pharmaceutica
Frost and Sullivan Honors Oramed with the 2009 European Oral Drug Delivery Technology JERUSALEM, Israel, August 25 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com), a developer of oral delivery systems, today announced that it i
Read more →ORMPUnassociated Document Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., chosen to lecture at the 2009 British Pharmaceutical Conference in Manchester, England
Chief Scientific Officer, Miriam Kidron, Ph.D., chosen to lecture at the 2009 British Pharmaceutical Conference in Manchester, England Israel - August 18, 2009- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of alternative drug delivery syst
Read more →ORMPUnassociated Document Oramed Pharmaceuticals was Awarded an NIS 3.1 million Grant from the Israeli Office of the Chief Scientist
Pharmaceuticals was Awarded an NIS 3.1 million Grant from the Israeli Office of the Chief Scientist Israel - August 4, 2009- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, today reported that its wholly owned Israel
Read more →ORMPOramed Pharmaceuticals Reports Positive Results from a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
Pharmaceuticals Reports Positive Results from a Study of Oral Insulin Capsule on Type 1 Diabetic Patients Israel - July 21, 2009- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of alternative drug delivery systems, today reported positive r
Read more →ORMPUnassociated Document Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI-BIOMED Conference, Israel 2009
Pharmaceuticals to Present at the 8th National Life Science & Week ILSI-BIOMED Conference, Israel 2009 Israel - June 10, 2009 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; www.oramed.com), a developer of oral delivery systems, announced that Oramed was chosen to present at
Read more →ORMPOramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule Israel - May 5, 2009 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; www.oramed.com), a developer of oral delivery systems, announced that Phase 2b clinical trials will co
Read more →ORMPUnassociated Document Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA) Israel - March 25, 2009 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; www.oramed.com), a developer of oral delivery systems, announced
Read more →ORMPOramed Pharmaceuticals Presents Results of Oral Administration of Exenatide-4; Proof of Concept Pharmacodynamic Study in Dogs The study suggests that the GLP-1analog exenatide -4 when combined with
Pharmaceuticals Presents Results of Oral Administration of of Concept Pharmacodynamic Study in Dogs suggests that the GLP-1analog exenatide -4 when combined with promoters is absorbed through the gastrointestinal tract and retains its Israel - November 14, 2008- Oramed Pharma
Read more →ORMPOramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository An insulin suppository represents an important development in the treatment of diabetes as it provides a painless alternative for effective insul
Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository insulin suppository represents an important development in the treatment diabetes as it provides a painless alternative for effective insulin delivery Israel - October 23, 2008 - Oramed Pharmaceuticals, Inc. (
Read more →ORMPORAMED PHARMACEUTICALS COMMENCES PHASE 2A TRIALS OF ITS ORAL INSULIN CAPSULE ON TYPE 1 DIABETICS Study to assess the safety and efficacy of ORMD 0801,oral insulin capsule, on Type 1 diabetics
PHARMACEUTICALS COMMENCES PHASE 2A TRIALS OF ITS INSULIN CAPSULE ON TYPE 1 DIABETICS assess the safety and efficacy of ORMD 0801,oral insulin capsule, on Type 1 Israel - September 24, 2008 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; developer of oral delivery systems, ann
Read more →ORMPUnassociated Document Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform ORMD 0901 is being developed as an oral dosage form of a GLP1-analog aimed at improving glycemic
Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug is being developed as an oral dosage form of a GLP1-analog aimed at improving glycemic control in adults with type 2 diabetes Israel - September 16, 2008 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB)
Read more →ORMPOramed Pharmaceuticals Partners with ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801 ORMD 0801 to be tested on Type 2 Diabetic Volunteers
Pharmaceuticals Partners with ETI Karle Clinical to 2B Trials on Its Oral Insulin Capsule, ORMD 0801 to be tested on Type 2 Diabetic Volunteers Israel - September 9, 2008 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; developer of oral delivery systems, announced today the s
Read more →ORMPOramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule The trial demonstrated the safety and efficacy of the ORMD 0801- oral insulin capsule
Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin demonstrated the safety and efficacy of the ORMD 0801- oral insulin capsule Israel - August 6, 2008 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; developer of oral delivery systems, announced to
Read more →ORMPOramed Pharmaceuticals Raises $5 Million Through a Private Placement The Equity Financing was led by Montaur Capital Partners
Pharmaceuticals Raises $5 Million Through a Private Placement - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; www.oramed.com), developer of oral delivery systems, announced today that it has completed a raise of $5 million in a private placement of 8,668,002 shares common st
Read more →ORMPOramed Pharmaceuticals Partners with OnQ Consulting for Phase 2B Trials on its Oral Insulin Capsules Agreement signed with South African CRO to Conduct Phase 2B Trials
Pharmaceuticals Partners with OnQ Consulting for 2B Trials on its Oral Insulin Capsules signed with South African CRO to Conduct Phase 2B Trials Israel - April 17, 2008 - Oramed Pharmaceuticals, Inc. (ORMP.OB, www.oramed.com) announced today the signing of an agreement with O
Read more →ORMPOramed Pharmaceuticals Commences Phase 2A Clinical Trials in Israel Oramed Begins Studies on its Oral Insulin Capsule at Hadassah Medical Center
Pharmaceuticals Commences Phase 2A Clinical Trials in Begins Studies on its Oral Insulin Capsule at Hadassah Medical Israel - April 14, 2008 - Oramed Pharmaceuticals, Inc., (OTCBB: ORMP, www.oramed.com), a developer of oral delivery systems, commenced Phase 2A studies on its
Read more →ORMPOramed Pharmaceuticals Granted Approval to Conduct Phase 2A Trials of Its Oral Insulin Capsule Study Designed to Evaluate Safety and Efficacy on Type II Diabetic Volunteers
Pharmaceuticals Granted Approval to of Its Oral Insulin Capsule Designed to Evaluate Safety and Efficacy on II Diabetic Volunteers Israel - March 18, 2008 -- Oramed Pharmaceuticals Inc. (OTCBB:ORMP, www.oramed.com) has been granted approval the Institutional Review Board (I
Read more →ORMPOramed Pharmaceuticals Successfully Completes Phase 1B Clinical Trials Of Oral Insulin Capsule Phase 2A Trials Planned For Second Quarter 2008
Pharmaceuticals Successfully Completes 1B Clinical Trials Of Oral Insulin Capsule 2A Trials Planned For Second Quarter 2008 Israel - March 11, 2008 -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB http://www.oramed.com), a developer of oral delivery systems, has successfully
Read more →ORMPSource: Oramed Pharmaceuticals, Inc. Oramed Pharmaceuticals Teams up with OnQ Consulting Wednesday January 30, 8:34 am ET Biotechnology Company Signs Agreement with South African CRO to Conduct Phase 1 Tria
Oramed Pharmaceuticals Teams up with OnQ Wednesday January 30, 8:34 am ET Biotechnology Company Signs Agreement with South African CRO to Conduct Phase 1 Trials with Rectal Application of Insulin JERUSALEM--(BUSINESS WIRE)--Oramed Pharmaceuticals, Inc. (ORMP.OB, www.oramed.c
Read more →ORMPOramed Pharmaceuticals Signs Manufacturing Agreement for Oral Insulin Pill Jerusalem, Israel
Oramed Pharmaceuticals Signs Manufacturing Agreement for Oral Insulin Jerusalem, Israel November 2, Oramed Pharmaceuticals, Inc., a publicly traded company on both the OTCBB with the symbol ORMP and on the Frankfurt exchange under the ticker OJU, is pleased to announce they h
Read more →ORMPINTEGRATED SECURITY TECHNOLOGIES, INC. 1500 885 West Georgia Street Vancouver, B.C. V6C 3E8
INTEGRATED SECURITY TECHNOLOGIES, INC. 1500 885 West Georgia Street This letter sets out the agreement ( Agreement ) reached among Integrated Security Technologies, Inc. as purchaser ( IST ) and Hadasit Medical Research Services and Development Ltd. ( Hadasit ) regarding the tr
Read more →ORMPform8-kfeb806exh99_1.pdf -- Converted by SECPublisher 4.0, created by BCL Technologies Inc., for SEC Filing THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO
THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE 1933 ACT ). NONE OF
Read more →Competitive Position
How ORMP ranks across every disease it competes inCompetitive Position is a premium feature
See how ORMP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial